What question did this study set out to answer?

To correct inaccuracies in the assessment of exposure-safety relationships for antibody-drug conjugates (ADCs) approved by the FDA.

April 5, 2026Open Access

Erratum: A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025

Key Points

To correct inaccuracies in the assessment of exposure-safety relationships for antibody-drug conjugates (ADCs) approved by the FDA.
Review of antibody-drug conjugates approved from 2000 to 2025.
Identification and correction of errors in safety data presented in previously published tables.
An error was identified in the classification of interstitial lung disease for datopotamab deruxtecan.
Corrected safety data is now accurately reflected in the updated summary of E-R relationships.

Abstract

69 https://tcpharm.orgIn the original publication, an error was identified in Table 2 (Summary of E-R relationships and FDA assessments for ADCs).In the row for datopotamab deruxtecan (2025), interstitial lung disease (ILD) was incorrectly listed under the exposure-safety relationship (ADC) column.The corrected entry is shown below.The authors apologize for this error and any confusion it may have caused. Table 2 (excerpt). Summary of E-R relationships and FDA assessments for ADCs Before correctionAfter correction

Bookmark

View Full Paper

Cite This Study

Koo et al. (Thu,) studied this question.

synapsesocial.com/papers/69d1fc4fa79560c99a0a1e89 https://doi.org/https://doi.org/10.12793/tcp.2026.34.e3

Bookmark

View Full Paper